新股消息 | 迪哲医药(688192.SH)递表港交所

Group 1 - The core viewpoint of the article is that Dize Pharmaceutical (688192.SH) has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - Dize Pharmaceutical is a commercial-stage biopharmaceutical company focusing on the treatment of oncology and hematological diseases [1] - The company's flagship product, Shuwozhe®, is the only approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor globally for treating EGFR exon 20 insertion mutation lung cancer [1]